13.01.2015 Views

FORM 20-F Grupo Casa Saba, S.A.B. de C.V.

FORM 20-F Grupo Casa Saba, S.A.B. de C.V.

FORM 20-F Grupo Casa Saba, S.A.B. de C.V.

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Table of Contents<br />

Legal and Advisory Services. During <strong>20</strong>11, Mijares, Angoitia, Cortés y Fuentes, S.C., a Mexican law firm, provi<strong>de</strong>d us with legal and advisory services, and we expect<br />

that this will continue to be the case in the future. Francisco Fuentes Ostos, a partner from the law firm of Mijares, Angoitia, Cortés y Fuentes, S.C., is the secretary of our Board of<br />

Directors, without being a member of such Board. We believe that the fees we paid for these services were comparable to those that we would have had to pay a third-party law firm for<br />

similar services.<br />

Tax Advisory Services. During <strong>20</strong>11, Chevez, Ruiz, Zamarripa y Cia, S.C., a tax advisory firm, provi<strong>de</strong>d us with tax advisory services, and we expect that this will<br />

continue to be the case in the future. We believe that the fees we paid for these services were comparable to those that we would have had to pay a third party for similar services.<br />

During <strong>20</strong>11, we had no other related party agreements, except for the balances and transactions referred to above. We believe that all related party transactions were<br />

agreed upon on an arm’s-length basis.<br />

Item 8.<br />

Financial Information<br />

See “Item 18. Financial Statements” and “Item 19. Exhibits—In<strong>de</strong>x to Consolidated Financial Statements,” which are incorporated herein by reference.<br />

Material Legal Proceedings<br />

As of December 31, <strong>20</strong>11, except for the lawsuit filed by Farmacias Cruz Ver<strong>de</strong>, S.A. against FASA and as otherwise disclosed in Note <strong>20</strong> of the consolidated financial<br />

statements, there were no existing material legal proceedings that could have an adverse effect on the Company’s financial position or profitability.<br />

On December 9, <strong>20</strong>08, the Chilean Antitrust Authority or Fiscalía Nacional Económica initiated a procedure against FASA before the Chilean Antitrust Court or<br />

Tribunal <strong>de</strong> Defensa <strong>de</strong> la Libre Competencia, such procedure inten<strong>de</strong>d, among others, to prove that FASA had agreed with its competitors, Farmacias Cruz Ver<strong>de</strong> S.A. (“Cruz Ver<strong>de</strong>”) y<br />

Farmacias Salcobrand S.A. (“Salcobrand”) a mechanism to fix the price of medicines, to impose certain fines to FASA and to end the alleged agreement. On March 23, <strong>20</strong>09, The Chilean<br />

Antitrust Authority and FASA filed a settlement agreement before the Chilean Antitrust Court, which was approved on April 13, <strong>20</strong>09. Although the investigation is now over with<br />

respect to FASA due to the approval of the settlement agreement, this process continued in <strong>20</strong>11 with respect to FASA’s aforesaid competitors. Last January 31, <strong>20</strong>12, Cruz Ver<strong>de</strong> and<br />

Salcobrand were con<strong>de</strong>mned by the Chilean Antitrust Court and both companies challenged the applicable judgment; the Supreme Court Justice of Chile shall resolve this lawsuit.<br />

Prior to the notification of the judgment against Cruz Ver<strong>de</strong> and Salcobrand, on August 17, <strong>20</strong>11, Cruz Ver<strong>de</strong> instituted a civil action in or<strong>de</strong>r to obtain from FASA the<br />

payment of damages and lost profits, <strong>de</strong>rived from the so-called antitrust acts related to the settlement agreement. However, in this agreement FASA only acknowledged its own acts<br />

and did not make any accusations against Cruz Ver<strong>de</strong> and/or Salcobrand. Therefore, it is unlikely that either of these parties would win a lawsuit against FASA.<br />

In case Cruz Ver<strong>de</strong> and Salcobrand obtain the amendment of the judgment against them, Salcobrand could also sue FASA claiming the payment of consequential<br />

damages arising from the antitrust process such competitors were a party to. If FASA is unable to address such suits and win the processes that may be initiated against it, the<br />

occurrence of any of these factors could have a material adverse impact on our business and our financial results.<br />

Divi<strong>de</strong>nd Policy<br />

Pursuant to Mexican law, <strong>de</strong>cisions regarding the payment and amount of divi<strong>de</strong>nds are subject to approval of our sharehol<strong>de</strong>rs, generally, but not necessarily, on the<br />

recommendation of the Board of Directors. Our controlling sharehol<strong>de</strong>r owns 85% of our outstanding Ordinary Shares and, so long as it continues to own a majority of our outstanding<br />

shares, it will have the ability to <strong>de</strong>termine whether we will <strong>de</strong>clare and pay divi<strong>de</strong>nds, in cash or otherwise. See “Item 3. Key Information—Risk Factors—Risk Factors Related to our<br />

Securities—Our Controlling Sharehol<strong>de</strong>r Has the Ability to Restrict the Payment and Amount of Divi<strong>de</strong>nds”. We do not have a specific divi<strong>de</strong>nd policy. Depending on the results and<br />

condition of our business, divi<strong>de</strong>nds for a specific year would be paid to the extent that such payment would not impair our ability to invest and grow. Therefore, any divi<strong>de</strong>nd payment<br />

would <strong>de</strong>pend on the cash that the Company generates in a specific year and the Company’s liquidity and capital requirements as well as on the market conditions of our business.<br />

97

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!